# Immunotherapy resistance

> A figure of why cancer immunotherapy fails. Three 3D scenes contrast a hot (inflamed) tumour, where T cells reach the cancer cells, with a cold (immune-desert) tumour that keeps them out, and an exhausted T cell co-expressing PD-1, LAG-3 and TIM-3. Over the immunoediting escape frame, it sets out the mechanisms of primary and acquired resistance — immune exclusion, antigen and MHC loss, interferon-pathway mutations and T-cell exhaustion.

- Page: https://www.labcanvas.com/templates/cancer-biology/immunotherapy-resistance
- Open in the LabCanvas editor (LabCanvas account): https://www.labcanvas.com/editor.html?template=immunotherapy-resistance
- Updated: 2026-10-14
- Category: Cancer biology
- Method: Graphical abstract
- Product: Why checkpoint blockade works in some tumours and not others
- Key result: Resistance is primary, adaptive or acquired; it is the overarching "escape" phase of cancer immunoediting (Sharma et al. 2017; Schreiber et al. 2011)
- Figure: 1920 × 1080 px, 50 editable layers (1 generated objects with settings)

## Steps

1. **Hot vs cold**: Inflamed (hot) tumours have T cells among the cancer cells and respond; immune-excluded and desert (cold) tumours keep T cells out and resist (Chen & Mellman 2017)
2. **Antigen & MHC loss**: Tumours lose the neoantigens or the MHC-I (β2-microglobulin) that display them, so T cells can no longer see them (Sharma et al. 2017; Zaretsky et al. 2016)
3. **Interferon-pathway mutations**: Loss of JAK1/JAK2 blunts the response to interferon-γ and PD-L1 induction, giving acquired resistance (Zaretsky et al. 2016)
4. **T-cell exhaustion**: Persistent antigen drives T cells into exhaustion, co-expressing PD-1, LAG-3 and TIM-3 with lost effector function (Wherry & Kurachi 2015)

## Uses

- Immuno-oncology review and graphical-abstract figures
- Talks on resistance to checkpoint blockade
- Teaching hot vs cold tumours and exhaustion

## References

1. Chen & Mellman, “Elements of cancer immunity and the cancer–immune set point”, Nature 2017. https://doi.org/10.1038/nature21349 (review)
2. Sharma et al., “Primary, adaptive, and acquired resistance to cancer immunotherapy”, Cell 2017. https://doi.org/10.1016/j.cell.2017.01.017 (review)
3. Wherry & Kurachi, “Molecular and cellular insights into T cell exhaustion”, Nat. Rev. Immunol. 2015. https://doi.org/10.1038/nri3862 (review)
4. Zaretsky et al., “Mutations associated with acquired resistance to PD-1 blockade in melanoma”, N. Engl. J. Med. 2016. https://doi.org/10.1056/NEJMoa1604958 (primary)
5. Schreiber, Old & Smyth, “Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion”, Science 2011. https://doi.org/10.1126/science.1203486 (review)

Credit: Drawn in LabCanvas after Chen & Mellman, Nature 2017 (doi:10.1038/nature21349); Sharma et al., Cell 2017 (doi:10.1016/j.cell.2017.01.017); Wherry & Kurachi, Nat. Rev. Immunol. 2015 (doi:10.1038/nri3862); Zaretsky et al., NEJM 2016 (doi:10.1056/NEJMoa1604958); and Schreiber, Old & Smyth, Science 2011 (doi:10.1126/science.1203486). Schematic.

## Questions

**What does the “Immunotherapy resistance” template show?** A figure of why cancer immunotherapy fails. Three 3D scenes contrast a hot (inflamed) tumour, where T cells reach the cancer cells, with a cold (immune-desert) tumour that keeps them out, and an exhausted T cell co-expressing PD-1, LAG-3 and TIM-3. Over the immunoediting escape frame, it sets out the mechanisms of primary and acquired resistance — immune exclusion, antigen and MHC loss, interferon-pathway mutations and T-cell exhaustion.

**What are the steps shown in “Immunotherapy resistance”?** 1. Hot vs cold: Inflamed (hot) tumours have T cells among the cancer cells and respond; immune-excluded and desert (cold) tumours keep T cells out and resist (Chen & Mellman 2017). 2. Antigen & MHC loss: Tumours lose the neoantigens or the MHC-I (β2-microglobulin) that display them, so T cells can no longer see them (Sharma et al. 2017; Zaretsky et al. 2016). 3. Interferon-pathway mutations: Loss of JAK1/JAK2 blunts the response to interferon-γ and PD-L1 induction, giving acquired resistance (Zaretsky et al. 2016). 4. T-cell exhaustion: Persistent antigen drives T cells into exhaustion, co-expressing PD-1, LAG-3 and TIM-3 with lost effector function (Wherry & Kurachi 2015).

**Which papers is “Immunotherapy resistance” based on?** Chen & Mellman, “Elements of cancer immunity and the cancer–immune set point”, Nature 2017 (doi:10.1038/nature21349); Sharma et al., “Primary, adaptive, and acquired resistance to cancer immunotherapy”, Cell 2017 (doi:10.1016/j.cell.2017.01.017); Wherry & Kurachi, “Molecular and cellular insights into T cell exhaustion”, Nat. Rev. Immunol. 2015 (doi:10.1038/nri3862); Zaretsky et al., “Mutations associated with acquired resistance to PD-1 blockade in melanoma”, N. Engl. J. Med. 2016 (doi:10.1056/NEJMoa1604958); Schreiber, Old & Smyth, “Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion”, Science 2011 (doi:10.1126/science.1203486).

**Can I edit the “Immunotherapy resistance” template?** Yes. Open it in the LabCanvas editor: all 50 layers are editable, including 1 generated objects (structures, plots, equipment) with their own settings. Change the text, colours and layout, then export PNG, TIFF or PDF at the width and DPI the journal asks for.

**Do I need an account to use this template?** Not to view it here. To open and edit it, sign in to LabCanvas or create a free account (the free plan keeps up to 3 designs). Downloading the figure is part of LabCanvas Pro (US$19 a month or US$199 a year).
